Finerenone Outperforms Spironolactone for Cardiorenal Protection in Moderate CKD
🔓 Free Teaser Analysis Nephrology / Renal Pharmacy Confirmatory Grade: Moderate
Georgianos PI, Leptokaridou-Mourtzila E, Kourtidou C, et al.
Jul 20, 2026 · Published in: American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Also in Cardiology
Finerenone emerges as the safer choice for CKD patients.
UK Kidney Association Guideline Sets Anticoagulation Framework for AF in Advanced CKD and Dialysis
Guideline Nephrology / Renal Pharmacy Confirmatory Grade: Low
Parker K, Power A, Buka R, et al.
Nov 15, 2026 · Published in: BMC Nephrology
Managing AF in CKD patients is challenging due to bleeding risks.
ICRAKI: Initial Intermittent Dialysis Linked to Higher Mortality Than Continuous Therapy
★ Editor's Pick Analysis Nephrology / Renal Pharmacy Practice-changing Grade: Moderate
Gaudry S, Boubaya M, Louis G, et al.
Oct 29, 2026 · Published in: N Engl J Med
Also in Critical Care / ICU
Continuous therapy might reduce mortality in critically ill kidney injury patients.
Dosing Through CRRT: Delivered Clearance, Not eGFR, Should Drive Drug Dosing
Analysis Pharmacokinetics / TDM Confirmatory Grade: Low
Pui MC, Lazar AE, Szederjesi J, et al.
Oct 27, 2026 · Published in: Pharmaceutics
Also in Critical Care / ICU, Nephrology
CRRT demands precise drug dosing adjustments in critical care settings.
AUC-Guided Vancomycin in Severe Renal Impairment: Underpowered but Directionally Favorable
Analysis Pharmacokinetics / TDM Hypothesis-generating Grade: Very Low
Fujita K, Yamamoto K, Itohara K, et al.
Oct 25, 2026 · Published in: Biological & Pharmaceutical Bulletin
Also in Infectious Disease / Antimicrobials, Nephrology
Can AUC-guided vancomycin dosing reduce kidney risk in renal impairment?
Oral Obesity Drugs Across CKM Stages: Only Semaglutide Has Outcomes Data
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Alhazmi A, Le Roux CW
Oct 14, 2026 · Published in: Drug Design, Development and Therapy
Also in Cardiology, Nephrology
Oral obesity drugs may redefine CKM syndrome treatment.
Semaglutide Plus Dapagliflozin: Short-Term Gains in Diabetic CKD
Analysis Nephrology / Renal Pharmacy Hypothesis-generating Grade: Very Low
Gong C, Luo Q, Li Q
Oct 9, 2026 · Published in: Medicine
Also in Endocrinology / Diabetes / Obesity
Could combining semaglutide and dapagliflozin benefit diabetic patients with kidney disease?
Sofosbuvir/Daclatasvir Matches Grazoprevir/Elbasvir at 100% SVR12 in Hemodialysis Hepatitis C
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Low
Sulaiman AS, Nugroho P, Bestari MB, et al.
Oct 8, 2026 · Published in: Acta Medica Indonesiana
Also in Infectious Disease / Antimicrobials, Nephrology
Sofosbuvir/daclatasvir proves effective for hepatitis C in hemodialysis patients.
SGLT2 Inhibitors in Diabetic CKD: Metabolic Wins, Neutral Surrogates
Analysis Nephrology / Renal Pharmacy Confirmatory Grade: Moderate
Shi X, Fu K, Hu M, et al.
Oct 2, 2026 · Published in: Medicine
Also in Endocrinology / Diabetes / Obesity
SGLT2 inhibitors offer metabolic benefits but risk volume depletion in diabetic CKD.
Pooled semaglutide trials show 16% lower kidney composite risk
Analysis Nephrology / Renal Pharmacy Confirmatory Grade: Moderate
Mann JFE, Badve SV, Baeres FMM, et al.
Oct 1, 2026 · Published in: The Lancet. Diabetes & Endocrinology
Also in Endocrinology / Diabetes / Obesity
Semaglutide offers potential kidney benefits in cardio-metabolic diseases.
Rituximab Achieves Moderate Renal Response in Difficult Lupus Nephritis
Analysis Rheumatology / Immunology Confirmatory Grade: Low
Wang X, Liang S, Sun X, et al.
Sep 29, 2026 · Published in: Clinical and Translational Science
Also in Nephrology
Rituximab provides moderate renal benefits in hard-to-treat lupus nephritis cases.
First 24 Hours Reveal Massive Medication Burden in Elderly CKD
Analysis Geriatrics / Geriatric Pharmacy Confirmatory Grade: Low
Mulej A, Marinović I, Matković I, et al.
Sep 24, 2026 · Published in: Pharmacy (Basel, Switzerland)
Also in Clinical Practice, Nephrology
Early hospital admission is key for optimizing elderly CKD pharmacotherapy.
Indirect Network Meta-Analysis Ranks Cardiorenal Drugs in Diabetic CKD
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Chen H, Wu X, Yuan M, et al.
Sep 23, 2026 · Published in: Frontiers in Endocrinology
Also in Nephrology, Cardiology
SGLT2 inhibitors show promise for renal outcomes in T2D-CKD.
Renal CDSS Improve Prescribing Processes but Not Proven Outcomes
Analysis Medication Safety Hypothesis-generating Grade: Low
Ismail A, Sauriasari R, Yanuar A, et al.
Sep 19, 2026 · Published in: F1000Research
Also in Nephrology
Clinical Decision Support Systems may boost medication safety in CKD patients.
KDIGO 2026 Anemia in CKD Guideline: ESA First, Proactive IV Iron in Hemodialysis
Guideline Nephrology / Renal Pharmacy Practice-changing Grade: Very Low
Hedayati SS, Babitt JL, Berns JS, et al.
Sep 15, 2026 · Published in: Ann Intern Med
Updated guidelines prioritize personalized anemia management in chronic kidney disease.